News
05-21-2010, 04:40 AM
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.
More... (http://www.news-medical.net/news/20100521/Provectus-to-present-further-positive-data-from-PV-10-Phase-2-clinical-trial-for-metastatic-melanoma-at-ASCO.aspx)
More... (http://www.news-medical.net/news/20100521/Provectus-to-present-further-positive-data-from-PV-10-Phase-2-clinical-trial-for-metastatic-melanoma-at-ASCO.aspx)